Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Random things, from AGM information

<< Previous

Bullboard Posts

Next >>

Comment by venture009on Apr 08, 2023 11:43pm

203 Views

Post# 35385617

RE:Random things, from AGM information

Canadafan, not long ago there was a prediction that we would have a buyout or partner by the end of March (Pfizer 90 exclusive), then it became obvious Pfizer had dropped out of the running and then the prediction something by the end of June after ASCO and the maturing of data would be known and now you are suggesting Q3 will be the NEW timeline. Please, enough already. The volume has dried up and there is very little interest in ONC from either market.

<< Previous

Bullboard Posts

Next >>

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide